Lupus nephritis is a serious complication of lupus that is caused by inflammation of the kidneys. It affects up to 60% of people with lupus and usually occurs within 5 years of diagnosis. If left ...

CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that on January 22, 2026, Health Canada has approved Gazyva® (obinutuzumab) for ...

Studies investigating what is damaging the kidney in lupus nephritis point to tubulointerstitial inflammation as an important risk factor. Tubulointerstitial inflammation in patients with lupus ...

The treatment has been approved for NHS use, offering new hope to the nearly 12,000 people in England living with lupus ...

DESTIN, Fla. — Despite new therapies and evolving research, lupus nephritis continues to present clinical and research challenges, according to a presenter at the Congress of Clinical Rheumatology ...

NICE has recommended obinutuzumab with mycophenolate for severe lupus nephritis after trials showed higher renal response and fewer flares.

Lupus nephritis is a serious complication of lupus — and because it doesn’t always cause symptoms right away, it’s important to find it early. Talk to your lupus doctor about getting screened (tested) ...

Regular assessment of renal function, proteinuria, and serological markers is crucial for monitoring lupus nephritis progression and treatment response. Long-term follow-up data offer valuable ...

Please provide your email address to receive an email when new articles are posted on . HUNTINGTON BEACH, Calif. — Non-nephritis lupus and lupus nephritis may actually be part of a spectrum of ...

Background The long-term trajectories of estimated glomerular filtration rate (eGFR) and their relation to early proteinuria ...